GlassScriptPhysician profile
Robert K Parangi
NPI 1528131281
$3,056.91
in general payments reported to CMS, 2019-2025
34 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $268 · 2021: $898 · 2022: $221 · 2023: $465 · 2024: $213 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $485.92 | 2021-2023 | |
| Glaxosmithkline, LLC. | $423.84 | 2019-2020 | |
| Pfizer INC. | $348.28 | 2019-2023 | |
| Braeburn INC. | $195.49 | 2023-2025 | Brixadi |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2021 | |
| Intra-Sana Laboratories | $119.90 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Allergan, INC. | $117.62 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $116.02 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.92 | 2021-2022 | |
| Lilly USA, LLC | $80.48 | 2019-2023 | Mounjaro |
| Collegium Pharmaceutical, INC. | $79.04 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $76.42 | 2021 | |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Exact Sciences Corporation | $65.65 | 2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $65.59 | 2023 | Wegovy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $58.55 | 2023-2024 | Kristalose |
| Otsuka America Pharmaceutical, INC. | $51.48 | 2022-2024 | Rexulti |
| Amgen INC. | $51.43 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $49.17 | 2019 | |
| Averitas Pharma INC. | $46.00 | 2023 | Qutenza |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Gilead Sciences, INC. | $41.46 | 2023-2024 | Epclusa |
| Daiichi Sankyo INC. | $40.84 | 2019 | |
| Boston Scientific Corporation | $30.23 | 2025 | Watchman Access System |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.77 | 2025 | |
| Baudax Bio INC. | $18.69 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.40 | 2022 | |
| Global Blood Therapeutics, INC. | $13.86 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.43 | 2022 | |
| Protega Pharmaceutials INC | $13.36 | 2023 | Roxybond |
| Currax Pharmaceuticals LLC | $12.81 | 2020 | |
| Virtus Pharmaceuticals LLC | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Parangi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.